The Global Insulin Market

Sales of rapid-acting analogues of insulin now exceed those for human sequence insulin. Humalog and Novolog (Novorapid) had combined sales totalling US$1555.2 million in 2005 compared with US$870.2 million for all other rapid-acting insulins, Humalog being the market leader. The intermediate-acting insulins, Humulin and Novolin (Insulatard) being the dominant examples, sold US$1050.8 million in 2005, which was a small decrease compared with 2004. The market (US$1576.8 million in 2005) for prolonged-duration analogues is dominated by Lantus, with Levemir gaining some ground since its introduction. All insulins, including premixed formulations with a sale of US$2256.1 million in 2005 and dominated by Novolog Mix, Novolin Mix and Humalog Mix, are used for both type 1 and type 2 diabetes (all data from [5]). As a consequence there has been a general increase in the use of insulin. Data from recent years in Denmark (with an estimated 25,000 patients with type 1 diabetes and more than 200,000 patients with type 2 diabetes) are shown in Fig. 1. Data from France [6] showed a

Total use of Insulins, Denmark

Total use of Insulins, Denmark

Insulin Market

Use of Fast-acting Insulins, Denmark

B

6.000

5.000

D

4.000

D

D

o

3.000

o

o

2.000

1.000

Use of Fast-acting Insulins, Denmark m

Use of Basal Insulins, Denmark

12000

10000

8000

6000

Use of Basal Insulins, Denmark

10000

8000

6000

4000 2000 0

-

2

2

2

2

2

1

o ro

CO

o

(Jl

I

Fig. 1. Trends in the use of insulin in Denmark in the new millennium, all insulins (defined daily doses, DDD) (A), fast-acting insulins (left human insulin, middle lispro, right aspart) (B), basal insulins (left glargine, middle detemir, right human insulin) (C). (From The Danish Medicines Agency at www.dkma.dk.) The numbers reflect the use of insulin in 44,467 patients in 2001, increasing to 56,501 in 2005. Total use of analogues is increasing.

4000 2000 0

Fig. 1. Trends in the use of insulin in Denmark in the new millennium, all insulins (defined daily doses, DDD) (A), fast-acting insulins (left human insulin, middle lispro, right aspart) (B), basal insulins (left glargine, middle detemir, right human insulin) (C). (From The Danish Medicines Agency at www.dkma.dk.) The numbers reflect the use of insulin in 44,467 patients in 2001, increasing to 56,501 in 2005. Total use of analogues is increasing.

tripling of the use of insulin from 1976 to 1989 most likely driven by the increasing burden of type 2 diabetes. In addition, the adjuvant use of novel amyli-nomimetics has gained some ground in the USA.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment